【摘 要】
：
On the basis of its immunomodulatory and antiangiogenic properties thalidomide has undergone clinical evaluation in various malignancies, including multiple myeloma, myelodysplastic syndromes, and oth
【机 构】
：
EVP of Pharmaceutical Development Celgene Corporation USA
【出 处】
：
BIT Life Sciences 1st Annual World Cancer Congess-2008(2008中
论文部分内容阅读
On the basis of its immunomodulatory and antiangiogenic properties thalidomide has undergone clinical evaluation in various malignancies, including multiple myeloma, myelodysplastic syndromes, and other hematological and solid tumors.To date it has been awarded regulatory approval for use in multiple myeloma in both the USA and recently in Europe.Structural analogs of thalidomide have been synthesized in order to explore potential molecular targets of thalidomide, as well as to identify new therapeutic areas.One class of analogs (IMiDs) is several thousand times more potent than thalidomide in regulating cytokines, stimulating T-cell proliferation, inhibiting angiogenesis, etc.Lenalidomide (Revlimid(R)) is an immunomodulatory and anti-angiogenic, second generation IMiD analog of thalidomide.Preclinical testing, including pharmacology, PK and toxicity studies has led to the identification of Revlimid as a potent drug candidate for use in oncology.Revlimid is an oral agent with an enhanced activity profile compared to thalidomide and is a compound with multiple activities of potential relevance to cancer.
其他文献
Peroxisome proliferator-activated receptors (PPAR) are members of the nuclear hormone receptor family involved in the expression of genes involved in several biologic cellular processes.There are thre
BACKGROUND: Increasing evidence indicates that the plasma membrane contains an essential electron transport system that is used particularly by highly glycolytic cancers to oxidize intracellular NADH
Mechanisms of broad cross-protection, as seen in viral infection and also applied to vaccines, emphasize pre-existing antibodies, CDS+ memory T cells, and accelerated B cell responses reactive with co
There is an increasing interest in exploring Artemisinin and its derivatives, clinically used antimalarial drugs, as novel anticancer agents.This presentation will focus on recent studies accomplished
The efficacy and toxicity ofa lysate-pulsed autologous dendritic cell (DC)-based vaccine were evaluated in patients with advanced colorectal cancer (CRC).DCs were cultured from peripheral blood mononu
Preclinical cancer models are commonly based on use of human cancer cell lines, such models, while valuable, in general do not adequately predict the efficacy of anticancer agents in the clinic To dev
This work discusses intranasal delivery ofperillyl alcohol (POH) as a potential adjuvant therapeutic strategy for patients with relapsing malignant gliomas.POH is a monoterpene with preclinical antitu
To understand metastasis of squamous cell carcinoma of the head and neck (SCCHN), we previously established a lymph node metastatic SCCHN xenograft mouse model and selected highly metastatic SCCHN cel
Cancer is one of the major causes of death in dogs and share similar incidence rates as in humans.Dogs develop spontaneously cancers at sites very analogous to those in humans and are more comparable
We have established a chicken model for high-throughput identification of genes directly involved in the genesis and progression of renal tumors and of solid tumors in general.The model is based on in